__NUXT_JSONP__("/drugs/Relmacabtagene_Autoleucel", (function(a,b,c){return {data:[{drug:{slug:b,emaEpar:[],fdaDrugLabel:[],id:b,nciThesaurus:{casRegistry:a,chebiId:a,chemicalFormula:a,definition:"A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed, costimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, relmacabtagene autoleucel target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.",fdaUniiCode:"K5CXA4X5U8",identifier:"C155878",preferredName:c,semanticType:"Cell",subclassOf:["C129826","C176018","C28681"],synonyms:["Autologous Anti-CD19 CAR T-cells JWCAR029","Autologous CD19-targeted CAR T Cells JWCAR029","JWCAR 029","JWCAR-029","JWCAR029","RELMACABTAGENE AUTOLEUCEL","Relma-cel",c]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FRelmacabtagene_Autoleucel",extension:".json",createdAt:"2021-10-30T13:34:14.133Z",updatedAt:"2021-10-30T13:34:14.143Z"}}],fetch:{},mutations:void 0}}("","Relmacabtagene_Autoleucel","Relmacabtagene Autoleucel")));